Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847125 | 0.94 | ADORA3 (0.53) | ADORA3ADORA2AADORA1ADORA2BACHE | |
| SCHEMBL1855867 | 0.90 | ADORA3 (0.51) | ADORA3ADORA2AADORA1ADORA2BACHE | |
| SCHEMBL1849890 | 0.90 | ADORA3 (0.44) | ADORA3ADORA2AADORA1ACHEGSK3B | |
| SCHEMBL1852777 | 0.89 | ADORA2A (0.52) | ADORA3ADORA2AADORA1ACHEGSK3A | |
| SCHEMBL1847202 | 0.88 | ACHE (0.47) | ADORA3ADORA2AADORA1ADORA2BACHE | |
| SCHEMBL1847530 | 0.88 | ADORA3 (0.59) | ADORA3ADORA2AADORA1ADORA2BACHE | |
| SCHEMBL3770544 | 0.88 | KDR (0.47) | ADORA3ADORA2AADORA1GSK3B | |
| SCHEMBL1850813 | 0.87 | ADORA3 (0.67) | ADORA3ADORA2AADORA1ADORA2BACHE | |
| SCHEMBL1848987 | 0.87 | ADORA3 (0.67) | ADORA3ADORA2AADORA1ADORA2BACHE | |
| SCHEMBL1848588 | 0.87 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410282-B2 | Compounds as adenosine A1 receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2013-04-02 | — | — | US | claimed |
| EP-2197860-B1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2011-05-25 | — | — | EP | claimed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | claimed |
| US-8410282-B2 | Compounds as adenosine A1 receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2013-04-02 | — | — | US | disclosed |
| EP-2197860-B1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2011-05-25 | — | — | EP | disclosed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | disclosed |
| EP-2197860-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009044250-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.